Catalog No.
Product Name
Application
Product Information
Citations
-
Amyloid-β Inhibitor
Hoechst 34580 tetrahydrochloride is a nuclear marker dye that selectively targets A/T-rich double-stranded DNA. This compound exhibits enhanced fluorescence intensity when bound to nucleic acids, making it valuable for live cell labeling applications. As the pH of the solution increases, the fluorescence intensity of Hoechst 34580 also increases, providing a reliable tool for studying cellular dynamics, DNA distribution, and nuclear morphology in real-time. This reagent is particularly useful in research focused on amyloid-β and related neurodegenerative processes. -
Histochemical Stain
X-34 is a lipophilic fluorescent derivative of Congo red, characterized by its bright yellow-green fluorescence. It selectively stains neuritic and diffuse plaques, neurofibrillary tangles, neuropil threads, and cerebrovascular amyloid in brain tissue. This reagent is widely utilized in research focused on Alzheimer's disease to facilitate the study of these key pathological features. - Pyridoxal 5′-phosphate monohydrate is the active coenzyme form of vitamin B6 and is essential for the function of numerous enzymes. It serves as a key cofactor for aromatic L-amino acid decarboxylase, which catalyzes the final step in the biosynthesis of the neurotransmitters dopamine and serotonin. Pyridoxal 5′-phosphate is the primary intracellular phosphorylated form of vitamin B6 and is interconvertible with other forms, including pyridoxine 5′-phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).
-
Vitamin B6 Derivative
Pyridoxal 5′-phosphate hydrate (PLP) is the biologically active form of vitamin B6 and serves as an essential cofactor for over 100 enzymatic reactions, particularly those involved in amino acid metabolism. It plays a critical role in the function of aromatic L-amino acid decarboxylase, the enzyme responsible for catalyzing the final step in the synthesis of key neurotransmitters such as dopamine and serotonin. PLP is the principal coenzyme form generated through intracellular phosphorylation of vitamin B6 precursors and is interconvertible with other phosphorylated forms, including pyridoxine 5′-phosphate (PNP) and pyridoxamine 5′-phosphate (PMP). - The Italian mutation of β-amyloid 1-40 (E22K) exhibits faster aggregation kinetics and greater neurotoxicity compared to the wild-type peptide. Solid-state NMR studies (Masuda et al.) suggest this enhanced toxicity may be linked to the formation of a salt bridge between Lys²² and Asp²³ in a minor conformer. Similar to the Arctic, Flemish, and Dutch Aβ variants, the Italian mutant also shows significantly reduced degradation by the Aβ-cleaving enzyme neprilysin, contributing to its pathological accumulation.
-
GSK3β Inhibitor
GSK3β-IN-3 is an ATP-competitive inhibitor of glycogen synthase kinase 3 beta (GSK3β), exhibiting an IC50 of 0.90 μM. It effectively lowers the phosphorylation levels of tau protein in the BR5706 strain and reduces the accumulation of amyloid-beta (Aβ) aggregates in the CL2006 strain. This compound is essential for research applications focused on Alzheimer's disease (AD), aiding in the understanding of neurodegenerative mechanisms and potential therapeutic strategies. -
hAChE/hBuChE Inhibitor
hAChE-IN-5 is a potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBuChE), exhibiting IC50 values of 0.17 μM for both enzymes. In addition, hAChE-IN-5 demonstrates significant GSK3β inhibition with an IC50 of 0.21 μM. This compound is utilized in research focused on tau protein aggregation and Aβ1-42 self-aggregation, effectively preventing Aβ-dependent neurotoxicity. Furthermore, hAChE-IN-5 can cross the blood-brain barrier, showcasing its potential as a multi-targeted agent in the study of Alzheimer's disease. -
Anti-aggregation Agent
CLR01 sodium is an anti-aggregation agent that effectively penetrates the blood-brain barrier. It inhibits the de novo aggregation of key proteins, including Amyloid-β 40/42, α-synuclein, IAPP, tau protein, and SOD1. CLR01 sodium has demonstrated the ability to reduce amyloid plaque burden in the cortex of triple-transgenic mice, resulting in improvements in memory and motor functions. This compound is applicable in research focused on neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). -
FLNA Modulator
Simufilam hydrochloride is an orally active modulator of filamin A (FLNA) that targets neuronal signaling pathways. This compound restores NMDAR signaling and Arc expression while inhibiting dysregulated mTOR activity. Additionally, it enhances insulin sensitivity and mitigates Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride is applicable in research related to Alzheimer's disease, particularly in understanding the underlying mechanisms of neurodegeneration. -
FLNA Modulator
Simufilam is an orally active modulator of filamin A (FLNA) that restores NMDA receptor (NMDAR) signaling and Arc expression. It effectively inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, which results in improved insulin sensitivity and a reduction in Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. This compound is particularly valuable for research applications focused on Alzheimer's disease and related neurodegenerative disorders. -
Neuroprotective Compound
REM127 is a neuroprotective small molecule that modulates calcium homeostasis in cells. It effectively restores calcium balance in cellular models affected by the pathological accumulation of tau protein, demonstrating potential to mitigate synaptic and cognitive deficits in Alzheimer's disease models. REM127 is capable of crossing the blood-brain barrier and may slow the progression of amyloid-beta and tau protein pathologies. This compound is suitable for research applications in neurodegenerative diseases. -
Aβ Aggregation Inhibitor
TDI-2760 is an Aβ aggregation inhibitor with an IC50 of 1.67 μM, specifically targeting the aggregation of amyloid-beta peptides. This compound effectively inhibits Aβ-fibrinogen interactions and modulates contact system activation induced by Aβ42. TDI-2760 is suitable for research focused on Alzheimer's disease, particularly in the study of vascular abnormalities associated with Aβ aggregation. -
Buffering Agent
HEPPS is a buffering agent with an effective pH range of 7.3 to 8.7. This compound has demonstrated the ability to reduce amyloid beta (Aβ) aggregate-induced memory deficits and improve cognitive functions in murine models. HEPPS is orally active and capable of crossing the blood-brain barrier, making it valuable for neuroscience research. -
TDP-43 Binder
rTRD01 is a selective TDP-43 binder that specifically targets the RRM1 and RRM2 domains of TDP-43, partially disrupting its interaction with c9orf72 repeat RNA while preserving binding to canonical sequences. This compound demonstrates significant neuroprotective effects in zebrafish models, improving motor function and providing protection against paraquat-induced neurodegeneration without teratogenic effects at elevated concentrations. rTRD01 is a valuable tool for investigating amyotrophic lateral sclerosis and related TDP-43 proteinopathies, offering insights into the molecular mechanisms involved in these conditions. -
β-amyloid (Aβ) Binder
Pittsburgh Compound B (PiB) is a targeted β-amyloid (Aβ) binder, designed as a PET tracer for the visualization of Aβ deposition in the brain. It exhibits a high affinity for Aβ(1-40) fibrils with a Ki value of 678.4 nM. The compound can be modified using click chemistry, allowing for the development of fluorescent conjugates for applications in fluorescence imaging and ultrastructural studies. Pittsburgh Compound B is particularly relevant for research focusing on Alzheimer's disease and the characterization of Aβ complexes. -
Amyloid-β 42 Inducer
Aftin-5 is an inducer of Amyloid-β 42 (Aβ42) that functions by modulating β-secretase and γ-secretase activity, leading to an increase in Aβ42 levels while decreasing Aβ38 levels. This compound affects mitochondrial ultrastructure, which is essential for its biological activity. Aftin-5 displays moderate cytotoxicity in various cell lines, including SH-SY5Y, HT22, N2a, and N2a-AβPP695, with IC50 values ranging from 150 μM to 194 μM. Its role in research makes it a valuable tool for studying Alzheimer's disease and related neurodegenerative conditions. -
BACE1/BACE2 Inhibitor
NB-360 is a potent dual inhibitor of β-secretase 1 and 2 (BACE1/BACE2) with IC50 values of 5 nM and 6 nM, respectively. This compound is brain-penetrable and orally active, effectively inhibiting the accumulation of amyloid-β proteins. NB-360 is valuable for research in inflammation and neurological diseases, particularly Alzheimer's disease. -
APP Degrader
APP degrader-1 is an orally active compound designed to target the amyloid precursor protein (APP). It induces the degradation of APP and effectively reduces the extracellular release of Aβ42. By binding to both CAPRIN1 and APP, APP degrader-1 enhances their interaction and facilitates CAPRIN1-mediated APP degradation via the endosome-lysosome pathway. This compound holds potential for research applications related to Alzheimer's disease and protein misfolding disorders. -
β-Amyloid
β-Amyloid (1-16) is a peptide fragment derived from β-Amyloid, known for its ability to bind various metal ions. This fragment plays a significant role in the formation of amyloid plaques, which are characteristic of Alzheimer's disease pathology. Researchers can utilize β-Amyloid (1-16) to investigate metal-induced aggregation mechanisms and assess its potential contributions to neurodegenerative processes associated with Alzheimer's disease. -
Amyloid Inhibitor
4-Hydroxyindole is an amyloid inhibitor that plays a critical role in the disruption of amyloid fibrillization. This compound has been shown to induce alterations in liver function, thyroid activity, and blood glucose levels in preclinical models. Its unique properties make 4-Hydroxyindole a valuable tool for investigating neurodegenerative diseases and metabolic disorders. Researchers can leverage its potential to explore therapeutic avenues for amyloid-related pathologies. -
TDP-43 Inhibitor
ACI-19626 is a TDP-43 inhibitor that targets TDP-43 aggregation. This compound is valuable for investigating the role of TDP-43 in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Its utility in preclinical studies helps elucidate the molecular mechanisms underlying these conditions and aids in the identification of potential therapeutic strategies. -
QPCTL Inhibitor
QP5038 is a specific inhibitor of the enzyme QPCTL, exhibiting an IC50 value of 3.8 nM. This compound demonstrates significant antitumor activity, making it a valuable tool for research in cancer biology. QP5038 can be utilized in studies focused on understanding the role of QPCTL in tumor metabolism and potential therapeutic strategies. -
PHF6/Tau Disrupter
Cl-NQTrp is a potent disrupter of preformed fibrillar aggregates associated with Tau-derived PHF6 (VQIVYK) peptides and full-length tau protein. This compound exhibits substantial activity in modulating tau aggregation, making it a valuable tool for research focused on tauopathies and Alzheimer's disease. Its role in disrupting tau pathology positions Cl-NQTrp as a key reagent for studies investigating therapeutic strategies against neurodegenerative disorders characterized by abnormal tau accumulation. -
Glutaminyl Cyclase Inhibitor
PBD-150 is a selective inhibitor of human glutaminyl cyclase (hQC), specifically targeting the Y115E-Y117E variant with a Ki value of 490 nM. This compound exhibits significant inhibitory activity, making it a valuable tool for studying the role of glutaminyl cyclase in neurodegenerative diseases. PBD-150 can be applied in research focused on pathologies associated with abnormal protein aggregation and its therapeutic potential. -
Aβ Aggregation Inhibtior
Dihydrochalcone is an Aβ aggregation inhibitor that destabilizes Aβ17-42 protofibrils by disrupting the β-sheet structure in the β1 region. This compound effectively targets both U-shaped Aβ40/Aβ42 and S-shaped Aβ42 protofibrils by binding to their respective protofibril cavities. Dihydrochalcone, primarily derived from the daemonorops draco tree, is of significant interest in Alzheimer's disease research and offers potential for studying therapeutic strategies aimed at preventing amyloid-beta aggregation. -
TFEB Activator
TFEB Activator 3 is a potent activator of TFEB, enhancing its nuclear translocation and promoting lysosome biogenesis. Demonstrated effects include a 44% increase in nuclear translocation at 10 µM after 3 hours and up to 97% at 30 µM under the same conditions. This compound is significant for research into Alzheimer’s disease, as it effectively crosses the blood-brain barrier, making it a valuable tool for studies on neurodegeneration and cellular clearance mechanisms. -
Bexarotene Derivative
OAB-14 is a derivative of Bexarotene that enhances the clearance of β-amyloid in APP/PS1 transgenic mice, addressing Alzheimer's disease-related pathologies and cognitive deficits. This compound demonstrates the ability to improve the functionality of the endosomal-autophagic-lysosomal pathway, making it a valuable tool for research into Alzheimer's disease mechanisms and potential therapeutic interventions. -
Amyloid-β Inhibitor
D-KLVFFA is a potent inhibitor of Amyloid-β assembly, exhibiting an IC50 value of 2.6 μM. This peptide is utilized in research focused on Alzheimer's disease, providing insights into the mechanisms of amyloid plaque formation and potential therapeutic interventions. Its application can contribute to the understanding of neurodegenerative processes and the development of Alzheimer’s disease treatments. -
Antioxidant Agent
Crocetin monomethyl ester serves as an antioxidant agent, derived from Crocus sativus. It exhibits significant anti-inflammatory and neuroprotective properties, making it valuable in neurological research. This compound promotes the clearance of amyloid-β by inducing autophagy through the STK11/LKB1-mediated AMPK pathway, highlighting its potential application in Alzheimer’s disease studies and related neurodegenerative disorders. -
Amyloid-Beta and Tau Inhibitor
Aβ/tau aggregation-IN-1 is a selective inhibitor of amyloid-beta (Aβ1-42) β-sheet formation and tau protein aggregation. With KD values of 160 μM for Aβ1-42 and 337 μM for tau, this compound demonstrates significant potential in research related to neurodegenerative disorders such as Alzheimer's disease. Its ability to cross the blood-brain barrier further supports its use in studies aimed at understanding the pathophysiology of amyloid and tau accumulation in the central nervous system. -
Aβ/tau Protein Aggregation Inhibitor
DN5355 is a small molecule inhibitor of amyloid β protein (Aβ) and hyperphosphorylated tau protein aggregation. It effectively inhibits the formation of Aβ and tau fibrils while also promoting the disaggregation of pre-formed aggregates. This compound is valuable for research applications focused on Alzheimer's disease and the underlying mechanisms of protein aggregation associated with neurodegeneration. -
Aβ40 Aggregation Inhibitor
Biphenyl-3′,3,4,4′-tetrol (BPT) is a potent inhibitor of Aβ40 aggregation, targeting the aggregation process associated with amyloid-beta peptides. This compound is relevant for research into neurodegenerative diseases, particularly Alzheimer's disease, by facilitating studies aimed at understanding and potentially mitigating the pathological effects of amyloid plaque formation. -
Amyloid-β Inhibitor
Semilicoisoflavone B is an isoflavone derived from Glycyrrhiza uralensis Fisch, functioning primarily as an inhibitor of amyloid-β (Aβ) secretion. It reduces Aβ levels by inhibiting the expression and activity of β-secretase-1 (BACE1). This compound enhances PPARγ expression while simultaneously inhibiting STAT3 phosphorylation, leading to decreased BACE1 levels. Semilicoisoflavone B is relevant for research into Alzheimer's disease and mechanisms of neurodegeneration. -
RAGE Ligand
MG-H1 is a ligand for the receptor for advanced glycation end products (RAGE), exhibiting a binding affinity (Kd) of 4.12 nM. It interacts specifically with human umbilical vein endothelial cells, making it a valuable tool for studying endothelial dysfunction. MG-H1 is particularly relevant in the context of diabetes research, where it aids in understanding the mechanisms of vascular complications associated with the disease. -
Aβ Inhibitor
Aβ aggregation-IN-1 is a selective inhibitor of amyloid-beta aggregation, effectively targeting the fibrillogenesis process. It demonstrates significant biological activity with IC50 values of 3.92 µM for aggregation and 7.19 µM for disaggregation. Additionally, Aβ aggregation-IN-1 inhibits malondialdehyde formation, enhances intracellular reduced glutathione levels, and reduces caspase 3 activity in neuronal cells. This compound is valuable for research in Alzheimer's disease and related neurodegenerative disorders. -
Amyloid β
β-Amyloid (1-37) (human) is a peptide derived from amyloid precursor protein, primarily targeting amyloid β. This biomarker is associated with cognitive decline and demonstrates a moderate correlation with Mini-Mental State Examination (MMSE) scores in Alzheimer's disease. β-Amyloid (1-37) serves as a valuable tool in research applications focused on Alzheimer's disease diagnosis and progression. -
Anti-amyloid Drug
Aβ/tau aggregation-IN-3 is a potent inhibitor of amyloid protein aggregation, demonstrating an IC50 of 0.85 μM in the Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. This compound exhibits significant anti-amyloid activity, making it a valuable tool for research into Alzheimer’s disease and other amyloid-related disorders. Its mechanism of action positions it as a promising candidate for investigations focused on therapeutic strategies aimed at reducing amyloid plaque formation. -
β-Amyloid
β-Amyloid (22-35) is a fragment comprising residues 22-35 of the β-amyloid protein. This compound exhibits cytotoxic effects on cultured rat hippocampal neurons in serum-free conditions. Additionally, β-Amyloid (22-35) has the capability to form aggregates and amyloid fibrils similar to those produced by full-length β-amyloid protein in neutral buffer solutions, making it a valuable tool for studying Alzheimer's disease pathology and neurodegeneration processes. -
Aβ42 Ligand
Aβ42 agonist-2 is a small molecule compound designed to target Aβ42 ligands. It facilitates the aggregation of Aβ42 by promoting the self-assembly of nontoxic aggregates and accelerating fibril formation through interactions with Aβ42 oligomers and pentamers. Additionally, Aβ42 agonist-2 has been shown to mitigate Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells, making it a valuable tool for investigating Alzheimer’s disease pathology and potential therapeutic strategies. -
Amyloid-β
β-Amyloid (1-20) is a peptide comprising the first 20 amino acids of the beta amyloid protein. This compound is primarily associated with the study of Alzheimer's disease and plays a crucial role in the formation of amyloid plaques. It is utilized in research applications investigating neurodegenerative processes, peptide aggregation, and the mechanisms underlying cognitive decline. -
Pyr Precursor
Amyloid β-Protein (3-42) is a precursor of pyroglutamate-modified Aβ, playing a critical role in the formation of amyloid plaques associated with Alzheimer's disease. This peptide contributes to the aggregation of Aβ(1-42), and its modified form, pEAβ(3-42), is known to accelerate Aβ(1-42) aggregation while inhibiting its nucleation processes. Research applications include studies on amyloid pathology and the mechanisms underlying Alzheimer's disease. -
β-Amyloid Inhibitor
RI-OR2-TAT is a potent inhibitor of β-Amyloid oligomerization, enhanced by the incorporation of the HIV protein transduction domain TAT. This compound exhibits a binding affinity to Aβ42 fibrils with a Kd value ranging from 58 to 125 nM. RI-OR2-TAT effectively reduces Aβ aggregation and plaque formation, mitigates microglial activation and oxidative stress, and promotes neurogenesis by increasing the proliferation of young neurons in the dentate gyrus. It is a valuable tool for research focused on neurodegenerative diseases, particularly Alzheimer's disease. -
Amyloid-beta 42 Binder
4-Sulfocalix[4]arene is an amyloid-beta 42 binder that exhibits a dissociation constant (Kd) of 5.39 µM, indicating a strong affinity for binding to this protein. Its ability to inhibit amyloid β-peptide fibrillation makes it a valuable tool in research focused on Alzheimer's disease pathology. Additionally, 4-Sulfocalix[4]arene can reduce the cytotoxicity associated with amyloid aggregates, providing insights for therapeutic strategies targeting amyloid-related neurodegeneration. -
Aβ Probe
MCAAD-3 is a near-infrared imaging probe designed to target amyloid-beta (Aβ) species, facilitating visualization of Aβ plaques in vivo. It possesses exceptional affinity for Aβ polymers, with a dissociation constant (Ki) exceeding 106 nM. This probe effectively permeates the blood-brain barrier, making it a valuable tool for studying Alzheimer’s disease and related neurodegenerative conditions in transgenic mouse models. -
Anti-Amyloid Agent
Anti-amyloid agent-1 is a potent anti-amyloid compound that effectively inhibits amyloid aggregation. This agent serves as a valuable tool for investigating amyloidosis and understanding its molecular mechanisms. Its application in research can aid in the development of therapeutic strategies for diseases associated with amyloid formation. -
Ecdysterones
2-O-Acetyl-20-hydroxyecdysone is an ecdysteroid that targets various biological pathways associated with insect and plant physiology. This compound has demonstrated efficacy in inhibiting amyloid-β42 (Aβ42)-induced cytotoxicity, potentially reducing the formation of neurotoxic Aβ oligomers by promoting their transformation into less harmful fibrils. Its biological activity suggests applications in research related to neurodegenerative diseases and the modulation of protein misfolding. -
Neuroprotective Agent
(-)-Clausenamide is a neuroprotective agent isolated from the leaves of Clausena lansium (Lour.) Skeels that enhances cognitive function under both normal and pathological conditions. It effectively inhibits β-amyloid (Aβ) toxicity and prevents neurofibrillary tangle formation by blocking tau protein phosphorylation. Additionally, (-)Clausenamide demonstrates significant neuroprotective activity against the Aβ25-35 peptide. This compound is valuable for research applications related to Alzheimer's disease (AD).
-
Luminescent Conjugated Oligothiophene Probe
h-FTAA is a luminescent conjugated oligothiophene (LCO) probe that selectively targets amyloid protein aggregates, including Aβ plaques. This compound enables the differentiation of various aggregate conformations through fluorescence signal changes. Additionally, h-FTAA has been shown to reduce the neurotoxicity of Aβ1-42 and the Arctic mutant Aβ (AβArc), providing protection to SH-SY5Y neuroblastoma cells. Its application includes the dynamic tracking of Aβ plaque formation and maturation processes, making it valuable for research in neurodegenerative diseases. -
Aβ42 Ligand
Aβ42 agonist-1 is a selective ligand targeting Aβ42, facilitating the aggregation of Aβ42 peptides. This compound interacts with Aβ42 oligomers and pentamers, promoting the self-assembly of nontoxic aggregates and accelerating the formation of fibrils. Additionally, Aβ42 agonist-1 effectively inhibits Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells, making it a valuable tool for research into Alzheimer's disease mechanisms and therapeutic strategies. -
Aβ1-40 Aggregation Inhibitor
QR-0217 is a potent inhibitor of Aβ1-40 aggregation, exhibiting an IC50 value of 7.5 µM. This compound also demonstrates the ability to inhibit α-synuclein aggregation, making it useful in studies related to neurodegenerative diseases. Additionally, QR-0217 has been shown to mitigate memory impairments associated with Aβ neurotoxicity, providing a valuable tool for research on Alzheimer's disease and related conditions.
